No endogenous mammalian target

The term 'No endogenous mammalian target' is a descriptive classification used in pharmacology to indicate that a specific drug or compound does not have a defined, functional protein or receptor target within the human or mammalian body. This category is typically assigned to anti-infective agents, such as certain antibiotics or antivirals, which are designed to selectively inhibit biological processes unique to pathogens like bacteria, viruses, or fungi (DrugBank, 2024). For example, beta-lactam antibiotics target bacterial cell wall synthesis, a process absent in mammalian cells (PubMed, PMID: 30256534). It may also refer to agents that exert therapeutic effects through non-specific physical or chemical interactions, such as osmotic laxatives or certain antacids (FDA, 2023). While the absence of a mammalian target is often a goal in drug design to ensure high selectivity and low host toxicity, it does not preclude the possibility of adverse effects. Safety concerns often arise from unintended off-target interactions where the drug binds to mammalian proteins with similar structural motifs or through the accumulation of reactive metabolites (StatPearls, 2023). Consequently, this designation serves as a critical distinction for biotech analysts and clinicians when evaluating the safety profile and mechanism of action of non-host-directed therapies.

Other names

Non-mammalian targetExogenous targetNo known mammalian targetNon-host target

Inhibition of non-mammalian biological processes or non-specific chemical/physical interaction